Diamyd Medical licenses candidate drug for diabetes and gluten intolerance

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announces today that it has entered into an exclusive license agreement for using the gluten protein gliadin for the treatment and prevention of type 1 diabetes. Diamyd Medical aims at evaluating combination regimens of gliadin with compounds and antigens, such as for example GABA and GAD, for shutting off the inflammatory component in type 1 diabetes, gluten intolerance and other inflammatory diseases, for which preliminary patent applications have been filed. The world market for a successful new drug for treatment and prevention